Drug development targeting the glycogen synthase kinase-3ß(GSK- 3ß)-mediated signal transduction pathway: Role of GSK-3β in adult brain

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 174-178

  Takashima, Akihiko ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Aging; Glycogen synthase kinase 3 (GSK 3 ); Memory reconsolidation; Neurofibrillary tangle (NFT)

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; HETEROZYGOTE; HUMAN; LONG TERM MEMORY; LONG TERM POTENTIATION; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROGRADE AMNESIA; SHORT SURVEY; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIAL; AGING; ANIMAL; BRAIN; DRUG DELIVERY SYSTEM; ENZYMOLOGY; GENETICS; MEMORY; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVIEW;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MEMORY; MICE; MICE, MUTANT STRAINS; SIGNAL TRANSDUCTION;

EID: 65449133185     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R29FM     Document Type: Short Survey

References (38)

1. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE. 2001;100:RE12.
2. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3 /factor A. Embo J. 1990;9:2431-2438.
3. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65:391-426.
4. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95-102.
5. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2006;9:309-317.
6. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006;7:1421-1434.
7. Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30:142-149.
8. O'Brien WT, Klein PS. Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiat. 2007;61: 139-141.
9. Iqbal K, Grundke-Iqbal I. Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Ann NY Acad Sci. 1996;777:132-138.
10. Lee VM, Trojanowski JQ. The disordered neuronal cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol. 1992;2:653-656.
11. Goedert M, Spillantini MG, Crowther RA. Tau proteins and neurofibrillary degeneration. Brain Pathol. 1991;1:279-286.
12. Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem (Tokyo). 1997;121:179-188.
13. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998;31:317-323.
14. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 1992;147:58-62.
15. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta over- expressing mice prevents tau hyperphosphorylation and neuro-fibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006;99:1445-1455.
16. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990-6995.
17. Boeve BF, Tremont-Lukats IW, Waclawik AJ, Murrell JR, Hermann B, Jack CR Jr, et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain. 2005;128:752-772.
18. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phos- phatidyl inositol-3 kinase and the activation of tau protein kinase I /glycogen synthase kinase-3 beta. Neurosci Lett. 1996;203:33-36.
19. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A. 1993;90:7789-7793.
20. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neuro-chem. 2002;83:1529-1533.
21. 21 Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neuro-degeneration. Neurobiol Aging. 2006;27:1258-1268.
22. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86-90.
23. Morris RGM, Inglis J, Ainge JA, Olverman HJ, Tulloch J, Dudai Y, et al. Memory reconsolidation: sensitivity of spatial memory to inhibition of protein synthesis in dorsal hippocampus during encoding and retrieval. Neuron. 2006;50:479-489
24. Dudai Y, Eisenberg M. Rites of passage of the engram: reconsoli-dation and the lingering consolidation hypothesis. Neuron. 2004;44:93-100.
25. Eisenberg M, Kobilo T, Berman DE, Dudai Y. Stability of retrieved memory: inverse correlation with trace dominance. Science. 2003;301:1102-1104.
26. Lee JLC, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci. 2006;26:10051-10056.
27. Biedenkapp JC, Rudy JW. Context memories and reactivation: constraints on the reconsolidation hypothesis. Behav Neurosci. 2004;118:956-964.
28. Riccio DC, Moody EW, Millin PM. Reconsolidation reconsidered. Integr Physiol Behav Sci. 2002;37:245-253.
29. Nader K, Schafe GE, LeDoux JE. The labile nature of consolidation theory. Nat Rev Neurosci. 2000;1:216-219.
30. Morris RG, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci. 2003;358:773-786.
31. Frey U, Morris RG. Synaptic tagging: implications for late maintenance of hippocampal long-term potentiation. Trends Neurosci. 1998;21:181-188.
32. Peineau S, Taghiiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. LTP Inhibits LTD in the hippocampus via regulation of GSK3/?. Neuron. 2007;53:703-717.
33. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007;25:81-86.
34. Diamond DM, Park CR, Campbell AM, Woodson JC. Competitive interactions between endogenous LTD and LTP in the hippocampus underlie the storage of emotional memories and stress-induced amnesia. Hippocampus. 2005;15:1006-1025.
35. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004;89:1313-1317.
36. Chapman PF, White GL, Jones MW, Coopr-Balcketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271-276.
37. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis. 2003;5:301-308.
38. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, et al. Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. Embo J. 2007;26:5143-5152.